Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 12, Issue 535, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aax2466
Keywords
-
Categories
Funding
- NIHR Oxford Biomedical Research Centre
- Innovative Medicines Initiative 2 Joint Undertaking [116019]
- European Union's Horizon 2020 research and innovation programme
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Wellcome Trust [WT105882MA]
Ask authors/readers for more resources
The development of an effective vaccine against respiratory syncytial virus (RSV) has been hampered by major difficulties that occurred in the 1960s when a formalin-inactivated vaccine led to increased severity of RSV disease after acquisition of the virus in the RSV season after vaccination. Recent renewed efforts to develop a vaccine have resulted in about 38 candidate vaccines and monoclonal antibodies now in clinical development. The target populations for effective vaccination are varied and include neonates, young children, pregnant women, and older adults. The reasons for susceptibility to infection in each of these groups may be different and, therefore, could require different vaccine types for induction of protective immune responses, adding a further challenge for vaccine development. Here, we review the current knowledge of RSV vaccine development for these target populations and propose a view and rationale for prioritizing RSV vaccine development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available